Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
HK

Holly Kordasiewicz

Head of Development, Ionis Pharmaceuticals

Appears in 1 story

Notable Quotes

The study hit all those objectives that it needed to hit on, even though it didn't hit on that primary endpoint.

Stories

Biogen's tau drug slows Alzheimer's decline in first-of-its-kind trial

New Capabilities

Co-developer of the drug's underlying technology

For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.

Updated 1 hour ago